Cargando…
Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
GnRH agonists (GnRHa) are a useful tool for pretreatment before artificial endometrial preparation for frozen-thawed embryo-transfer (FET). Their prolonged administration has been associated with thyroid dysfunction, both hyper and hypothyroidism. The aim of this study is to investigate the impact o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019438/ https://www.ncbi.nlm.nih.gov/pubmed/35465072 http://dx.doi.org/10.1155/2022/6331657 |
_version_ | 1784689277667377152 |
---|---|
author | Marin, Loris Ambrosini, Guido Noventa, Marco Filippi, Flavia Ragazzi, Eugenio Dessole, Francesco Capobianco, Giampiero Andrisani, Alessandra |
author_facet | Marin, Loris Ambrosini, Guido Noventa, Marco Filippi, Flavia Ragazzi, Eugenio Dessole, Francesco Capobianco, Giampiero Andrisani, Alessandra |
author_sort | Marin, Loris |
collection | PubMed |
description | GnRH agonists (GnRHa) are a useful tool for pretreatment before artificial endometrial preparation for frozen-thawed embryo-transfer (FET). Their prolonged administration has been associated with thyroid dysfunction, both hyper and hypothyroidism. The aim of this study is to investigate the impact of GnRHa administration on thyroid function in women undergoing artificial endometrial preparation. Seventy-eight euthyroid women undergoing endometrial preparation with hormone replacement for FET were retrospectively reviewed. They were divided into two groups according to pretreatment with GnRHa (group A, 42 women) or with an oral contraceptive (group B, 36 women). Group A was subsequently divided into two subgroups according to thyroid autoimmunity presence. Thyroid function has been evaluated and compared among groups and subgroups. Our results did not show any statistically significant differences in age, body mass index, and basal thyroid stimulating hormone (TSH). Total estradiol dosage, duration of treatment, and endometrial thickness were comparable among groups. When TSH was measured 14 days after embryo transfer, no significant differences between the two groups were reported. Among women of group A, TSH was significantly higher only in women with thyroid autoimmunity. GnRHa seems to be associated with thyroid dysfunction in women with thyroid autoimmunity undergoing hormone replacement therapy for FET. |
format | Online Article Text |
id | pubmed-9019438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90194382022-04-21 Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity Marin, Loris Ambrosini, Guido Noventa, Marco Filippi, Flavia Ragazzi, Eugenio Dessole, Francesco Capobianco, Giampiero Andrisani, Alessandra Int J Endocrinol Research Article GnRH agonists (GnRHa) are a useful tool for pretreatment before artificial endometrial preparation for frozen-thawed embryo-transfer (FET). Their prolonged administration has been associated with thyroid dysfunction, both hyper and hypothyroidism. The aim of this study is to investigate the impact of GnRHa administration on thyroid function in women undergoing artificial endometrial preparation. Seventy-eight euthyroid women undergoing endometrial preparation with hormone replacement for FET were retrospectively reviewed. They were divided into two groups according to pretreatment with GnRHa (group A, 42 women) or with an oral contraceptive (group B, 36 women). Group A was subsequently divided into two subgroups according to thyroid autoimmunity presence. Thyroid function has been evaluated and compared among groups and subgroups. Our results did not show any statistically significant differences in age, body mass index, and basal thyroid stimulating hormone (TSH). Total estradiol dosage, duration of treatment, and endometrial thickness were comparable among groups. When TSH was measured 14 days after embryo transfer, no significant differences between the two groups were reported. Among women of group A, TSH was significantly higher only in women with thyroid autoimmunity. GnRHa seems to be associated with thyroid dysfunction in women with thyroid autoimmunity undergoing hormone replacement therapy for FET. Hindawi 2022-04-12 /pmc/articles/PMC9019438/ /pubmed/35465072 http://dx.doi.org/10.1155/2022/6331657 Text en Copyright © 2022 Loris Marin et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Marin, Loris Ambrosini, Guido Noventa, Marco Filippi, Flavia Ragazzi, Eugenio Dessole, Francesco Capobianco, Giampiero Andrisani, Alessandra Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity |
title | Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity |
title_full | Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity |
title_fullStr | Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity |
title_full_unstemmed | Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity |
title_short | Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity |
title_sort | thyroid dysfunction after gonadotropin-releasing hormone agonist administration in women with thyroid autoimmunity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019438/ https://www.ncbi.nlm.nih.gov/pubmed/35465072 http://dx.doi.org/10.1155/2022/6331657 |
work_keys_str_mv | AT marinloris thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity AT ambrosiniguido thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity AT noventamarco thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity AT filippiflavia thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity AT ragazzieugenio thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity AT dessolefrancesco thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity AT capobiancogiampiero thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity AT andrisanialessandra thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity |